Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.48 |
| ▸ | MAP1LC3A | Q9H492 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLQ | O75417 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865632 | 1.00 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6870451 | 0.86 | LMNA (0.54) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6870457 | 0.86 | LMNA (0.54) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6867219 | 0.85 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6867213 | 0.85 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6867193 | 0.85 | MAP1LC3B (0.53) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6864426 | 0.85 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6867191 | 0.85 | MAP1LC3B (0.53) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6864425 | 0.85 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA | |
| SCHEMBL6869579 | 0.84 | HSP90AB1 (0.60) | HSP90AB1HSP90AA1MAP1LC3BMAP1LC3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | HSP90AB1 1949/4885HSP90AA1 2121/4885MAP1LC3B 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.